medigraphic.com

2007, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2007; 45 (6)

Implications of the Renin-Angiotensin System in Diabetic Nephropathy

Ortega-Pierres LE, Higareda-Mendoza AE, Pardo-Galván MA, Beltrán-Peña E, Gómez-García A, Farías-Rodríguez VM, Álvarez-Aguilar C

Language: Spanish
References: 71
Page: 601-610
PDF size: 171.87 Kb.


ABSTRACT

In the last decades, the incidence of type 2 diabetes has increased alarmingly worldwide including Mexico, and particularly among Mexican-Americans. The etiology of type 2 diabetes is multiple, in which there is a complex interaction between environmental and genetic risk factors. The kidney is a target organ that is damaged when type 2 diabetes occurs. The genetic predisposition for kidney disease in type 2 diabetes patients is the end result of the cumulative effects of multiple genetic and environmental factors. The components of the renin-angiotensin system and its genetic polymorphisms represent an area of intense research due to its association with kidney disease. Early identification of genetic risk factors for developing kidney disease could lead to timely treatment and may influence the response of the patients to drug therapy and diet recommendations.


REFERENCES

  1. ESRD Annual report. XII. International comparisons of ESRD therapy. Am J Kidney Dis 1999;34 (2 Suppl 1):S144-S151.

  2. Port FK. End-stage renal disease: magnitude of the problem, prognosis of future trends and possible solutions. Kidney Int 1995;50(Suppl1):S3-S6.

  3. Incidence and prevalence of ESRD. United Status Renal Data System 1999 Annual Data Report. Am J Kidney Dis 1999;34(Suppl 1):S40-S50.

  4. Mazzuchi N, Schwedt E, Fernández CJM, Cusumano AM, Soto K et al. Registro latinoamericano de diálisis y trasplante renal. Nefrol Latinoam 1996;2:309-331.

  5. Su-Hernández L, Abascal-Macías A, Méndez-Bueno FJ, Paniagua R, Amato D. Epidemiologic and demographic aspects of peritoneal diálisis in Mexico. Perit Dial Int 1996;16:362-365.

  6. Amato D, Álvarez-Aguilar C, Castañeda-Limones R, Rodríguez E, Ávila-Díaz M, Arreola F, et al. Prevalence of chronic kidney disease in an urban Mexican population. Kidney Int 2005;68(Suppl 97):S11-S17.

  7. Radecki SE, Nissenson AR. Hispanics with end stage renal disease. Ann Intern Med 1994;121: 723-724.

  8. Secretaría de Salud. Guía diagnóstico y terapéutica de la insuficiencia renal crónica. Disponible en http://www.hgm.salud.gob.mx/servmed/pdf/guias/GUIA_INSUF_RENAL_CRON.pdf.

  9. Velásquez-Monroy O, Rosas-Peralta M, Lara-Esqueda A, Pastelín-Hernández G, Grupo ENSA 2000, Attie F, et al. Hipertensión arterial en México: Resultados de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex 2002;72(1):71-84.

  10. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341: 1127-1133.

  11. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 2001;60:2041-2055.

  12. Jandeleit-Dahn, Cooper ME. Hypertension and diabetes. Curr Opin Nephrol Hypertens 2002;11: 221-228.

  13. Border WA, Yamamoto T, Noble NA. Transforming growth factor-β in diabetic nephropathy. Diabetes Metab Rev 1996;12:309-339.

  14. Pugliese G, Pricci F, Romeo G, Pugliese F, Mene P, Giannini S, et al. Up regulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via receptor-mediated mechanisms. Diabetes 1997;46:1881-1887.

  15. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-10461.

  16. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993;42:450-456.

  17. Minchenko AG, Stevens MJ, White L, Abatan OI, Komjáti K, Pacher P, et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly (ADP-ribose) polymerase activation. FASEB J 2003;17:1514-1516.

  18. Wang NS, Hirschberg R. Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Am J Physiol Renal Physiol 2000;278:F554-F560.

  19. Wolf G, Butzmann U, Wenzel UO. The reninangiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron 2003;93:3-13.

  20. Gilbert RE, Krumt H, Wilkinson-Berka J, Kelly DJ. The renin-angiotensin system and the longterm complications of diabetes: pathophysiological and therapeutic considerations. Diabetic Med 2003;20:607-621.

  21. Laragh JH, Lesson VI. The kidney-based plasma renin system in the servocontrol for blood pressure and sodium and potassium balance. En: Laragh’s lessons in renin system pathophysiology for treating hypertension and its fatal cardiovascular consequences. Elsevier Science; 2002. p. 22-25.

  22. Monteiro RM, Geraldo MJ. Alternative angiotensin II-forming pathways and their importance in physiological or physiopathological conditions. Arq Bras Cardiol 2002;78:432-438.

  23. Navar LG, Inscho EW, Majad SA, Imig JD, Harrison- Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev 1996;76:425-536.

  24. Wolf G, Ziyadeh FN, Zahner G, Stahl RAK. Angiotensin II stimulated expression of transforming growth factor beta in renal proximal tubular cells: attenuation after stable transfection with the c-mas oncogene. Kidney Int 1995;48:1818-1827.

  25. Ranwala SM, Lazar MA. Peroxisome proliferatoractivated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004;25:331-336.

  26. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, et al. Angiotensin II type II receptor over expression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999;104:925-935.

  27. Tea BS, Sarkissian SD, Touys RM, Hamet P, de-Blois D. Proapoptotic and growth inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo. Hypertension 2000;35:1069-1073.

  28. Dostal DE, Baker KM. The renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999;85:643-650.

  29. Hennes MMI, O’Shaughnessy IM, Kelly TM, La- Belle P, Egan BM, Kissebah AH. Insulin resistant lipolysis in abdominally obese hypertensive individuals: role of the renin-angiotensin system. Hypertension 1996;28:120-126.

  30. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003;14:274-281.

  31. Jan Danser AH, Schalekamp MADH. In there an internal cardiac renin-angiotensin system? Heart 1996;76(Suppl 3):28-32.

  32. Henrich WL, McAllister EA, Eskue A, Miller T, Moe OW. Renin regulation in cultured proximal tubule cells. Hypertension 1996;27:1337-1340.

  33. Christlieb AR. Renin-angiotensin-aldosterone system in diabetes mellitus. Diabetes 1976;25:820-825.

  34. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor 1 antigen. Kidney Int 1996;50: 1897-1903.

  35. Nguyen G, Bouzhir L, Delarue F, Rondeau F, Sraer JD. Evidence of a renin receptor on human mesangial cells: effects on PAI 1 and cGMP. Nephrologie 1998;19:411-416.

  36. Tallant EA, Diz DI, Ferrario CM. Antiproliferative actions of angiotensin (1-7) in vascular smooth muscle. Hypertension 1999;34:950-957.

  37. Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 2002;23:177-183.

  38. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo A. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000;58:251-259.

  39. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, et al. A novel angiotensin-converting enzyme related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87:E1-E9.

  40. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. J Biol Chem 2000;275: 33238-33243.

  41. Wolf G, Butzmann U, Wens U. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003;93:3-13.

  42. Lewis EJ, Hunaixker LG, Brain RP, Pohde RD. The effect of angiotensin converting enzyme inhibition in diabetic nephropathy. N Engl J Med 1993;323:1456-1462.

  43. Marre M, Lievre M, Catellier G, Mann JFE, Passa P, Ménar J. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomized, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004a;328:495-504.

  44. Parving HH, Lehnert H, Mortensen JB, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.

  45. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001;38:635-638.

  46. Gupta S, Clarkson MR, Duggan J, Brady HR. Connective tissue growth factor: potential role in glomeruloesclerosis and tubulointerstitial fibrosis. Kidney Int 2000;58:1389-1399.

  47. Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J, et al. Bone morphogenic protein 7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003;63:2037-2049.

  48. Wassef L, Langham RG, Kelly DJ. Vasoactive renal factors and the progression of diabetic nephropathy. Curr Pharm Des 2004;10:3373-3384.

  49. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensin II. Curr Opin Nephrol Hypertens 2001;10:321-329.

  50. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U, et al. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells: role of the angiotensin type II receptor. J Clin Invest 1997;100:1047-1058.

  51. Yu XQ, Wu LL, Huang XR, Yang N, Gilbert RE, Cooper ME, et al. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. Kidney Int 2000;58:1469-1480.

  52. Johnson R, Herrera-Acosta J, Schreiner GF, Rodríguez-Iturbe B. Subtle acquired renal injurie as a mechanism of salt-sensitive hypertension. N Engl J Med 2002;346:913-923.

  53. Tryggvason KJ. Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 1999;10: 2440-2445.

  54. Endlich K, Kriz W, Witzgall R. Update in podocyte biology. Curr Opin Nephrol Hypertens 2003; 10:331-340.

  55. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000;15:1379-1383.

  56. Steffes MW, Schmidt D, McCrery R, Basgen JM, Group ID. Glomerular cell number in normal subjects and in type I diabetic patients. Kidney Int 2001;59:2104-2113.

  57. Viedt C, Soto U, Krieger-Brauer HI, Fei J, Elsing C, Kubler W, et al. Differential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species. Arterioescler Thromb Vasc Biol 2000;20:940-948.

  58. Adler SH. Diabetic nephropathy: linking histology, cell biology and genetics. Kidney Int 2004;66: 2095-2106.

  59. Kobori H, Harrison-Bernard LM, Navar LG. Enhancement of angiotensinogen expression in angiotensin II-dependent hypertension. Hypertension 2001;37:1329-1335.

  60. Shinji T, Denan J, Michiko M, Mizuo M. The role of chymase in vascular remodeling and tissue fibrosis. Current Hypertens Rev 2005;1:159-168.

  61. Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, Burns KD. Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am J Physiol Renal Physiol 2001;280:F254-F265.

  62. Gumprecht J, Zychma MJ, Grzeszczak W, Zukowska-Szczechowska E. End-Stage Renal Disease Study Group. Angiotensin-I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. Kidney Int 2000;58:513-519.

  63. Tarnow L, Gluud Ch, Parving HH. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 1998;13:1125-1130.

  64. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, Mohn M, Tregear G, et al. Two putative active centers in human angiotensin I-converting enzyme reveled by molecular cloning. Proc Natl Acad Sci USA 1988;85:9386-9390.

  65. Hubert C, Houot AM, Corvol P, Soubrier F. Structure of the angiotensin I-converting enzyme gene. J Biol Chem 1991;266:15377-15383.

  66. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-1346.

  67. Rigat BC, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCPI) dipeptidyl-carboxy peptidase. Nucleid Acids Res 1992;20:1433.

  68. Poch E. Enzima de conversión de la angiotensina (ECA); polimorfismo I/D en hipertensión arterial y nefropatía. 1st Congress of Nephrology in Internet; Barcelona, España. Disponible en http://www.uninet.edu/cin2000/conferences/poch/poch.html.

  69. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002;277:14838-14843.

  70. Burrel ML, Johnston IC, Tikellis C, Cooper EM. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 2004;15:166-169.

  71. Ferrario CM. Commentary on Tikellis, et al. There is more to discover about angiotensin-converting enzyme. Hypertension 2003;41:390-391.




2020     |     www.medigraphic.com